Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of KMY Tablets in Healthy Subjects
NCT07314541Phase 1Recruiting
- Sponsor
- Lei Yun Shang
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing KMY Tablets with KMY Tablets Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 4 weeks and Maximum Observed Plasma Concentration up to 72 hours. Started Dec 2025; status: recruiting.
02
Drugs
KMY
Beyond the preview
Go deeper on NCT07314541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314541.